Aardvark Therapeutics to Present Data on Pipeline Programs at Upcoming ObesityWeek

Core Insights - Aardvark Therapeutics, Inc. is set to present at ObesityWeek 2025, showcasing its innovative approaches to treating metabolic diseases, particularly obesity [1][2] Presentation Details - Aardvark will present two key studies on November 4, 2025: - The first study focuses on TAS2R Pan-Agonist ARD-101, which has shown to reduce weight gain in mice and decrease hunger in adults with obesity [2] - The second study discusses an isoflavonoid modulator of oxidative metabolism (WE-868) with potential therapeutic applications in obesity and diabetes [2] Investor Engagement - An investor webinar is scheduled for November 5, 2025, where Aardvark will discuss data from ObesityWeek, featuring insights from key opinion leaders in obesity drug development and discussions on ARD-101's application in Prader-Willi Syndrome [3] Product Overview: ARD-101 - ARD-101 is a gut-restricted small molecule that acts as a pan-agonist for bitter taste receptors, stimulating the release of gut-peptide hormones like GLP-1 and CCK, which are crucial for hunger regulation [4] - The FDA has granted ARD-101 Orphan Drug Designation and Rare Pediatric Disease Designation for its use in Prader-Willi Syndrome [4] Product Overview: ARD-201 - ARD-201 is a fixed-dose combination of a DPP-4 inhibitor and ARD-101, designed to enhance the body's natural signals for fullness by prolonging the activity of gut hormones [6] - Aardvark is advancing ARD-201 in two Phase 2 trials: - The POWER trial aims to prevent weight regain in subjects who stop GLP-1RA therapy after significant weight loss [7] - The STRENGTH trial will evaluate the potential for placebo-adjusted weight loss and the additive effects of ARD-201 with GLP-1RA therapy [7] Product Overview: WE-868 - WE-868 is a novel small molecule that modulates mitochondrial energy metabolism and is currently under preclinical evaluation for obesity and diabetes treatment [8] Company Background - Aardvark Therapeutics is focused on developing small-molecule therapeutics to suppress hunger, particularly for conditions like Prader-Willi Syndrome and other metabolic diseases [9] - The company aims to address limitations of existing GLP-1 therapies through its innovative product pipeline [9]